<p align="justify"><u><strong>Gapping down</strong></u></p><p align="justify"><u>In reaction to disappointing earnings/guidance</u>: MVIS -9.9%, WX -6.4%, MLNK -4.5% (light volume), HRB -2.6% (also trading ex dividend), CASY -2.4%, TXN -1.4%, VVUS -0.7%... <u>Select financial related names showing weakness</u>: IRE -5.8%, AIB -3.9%, RBS -3.7%, NBG -3.4%, STD -2.7%, UBS -2.5%, CS -2.5%, ING -2.4%, BBVA -2.4%, HBC -2.3%, PUK -1.7%, BCS -1.5%, DB -1.5%... <u>Select metals/mining names trading lower:</u> RTP -2.4%, SLW -2.3%, EGO -2.2%, IAG -2.1%, BBL -2.0%, BHP -1.9%, NEM -1.6%, MT -1.3%... <u>Select oil/gas related names ticking lower:</u> STO -2.1%, PTR -1.1%, SLB -1.1%... <u>Other news</u>: HTM -11.6% (Announces $8.6 mln private placement financing), SCOK -7.9% (continued weakness from yesterday's 8 point decline), TTM -3.7% (Daimler sells equity interest in Tata Motors), FSLR -3.4% (still checking), SUSQ -3.0% (announces offering of $300 mln common stock and $50 mln cumulative trust preferred securities, series II), CMA -1.9% (announces it has commenced an $800 mln common stock offering, downgraded to Market Perform from Outperform at BMO Capital Markets), X -1.9% (still checking), CVX -0.9% (outlined plans to improve returns and streamline downstream portfolio and organization; Q1 charges for severance are currently estimated to be $150-200 mln)... <u>Analyst comments</u>: ZRAN -5.5% (downgraded to Hold at Collins Stewart), CAKE -2.1% (downgraded to Neutral at MKM Partners), TXT -2.0% (downgraded to Neutral from Overweight at JP Morgan ), TM -1.3% (downgraded to Hold at Standpoint Research),</p><p align="justify"><strong><u>Gapping up</u></strong></p><p align="justify"><u>In reaction to strong earnings/guidance</u>: CPE +17.4%, FRPT +11.3%, CHINA +10.8%, GAIA +8.4%, DIOD +2.7%, SNHY +2.4% (light volume)... <u>Other news</u>: HOKU +9.1% (receives $50 million from Tianwei Loan to finance polysilicon plant), ALKS +8.4% (still checking), IMGN +5.8% (announces orphan drug designation granted to IMGN901 for treatment of merkel cell carcinoma by US FDA and EU COMP), ACUR +4.9% (Acura Pharma and King Pharmaceuticals announce 'positive' top line results of a clinical study assessing relative abuse potential), SKX +3.4% (higher following positive Jim Cramer comments on growth story), GGP +1.6% (receives proposal for $3.925 bln in new equity capital from Fairholme Capital Management and Pershing Square Capital Management)... <u>Analyst comments</u>: CERS +8.1% (upgraded to Outperform at Baird), WRC +6.0% (upgraded to Outperform at Credit Suisse), CXDC +3.9% (initiated with a Buy at Canaccord Adams), HK +3.6% (upgraded to Outperform at Wells Fargo), LNCE +2.4% (upgraded to Buy from Hold at BB&T Capital Mkts), YUM +1.7% (upgraded to Buy at UBS), </p>